NCT03628586

Brief Summary

The main purpose of the study is to improve management and expedite safe discharge of patients presenting with chest pain with troponin ≤14ng/l using fifth generation, 'highly sensitive' troponin T. Our aim would be to specifically test in a prospective study whether biomarkers for left ventricular wall stress (NT pro brain natriuretic peptide), ischaemia (Heart-type fatty acid protein) and a novel marker of stress, raised in a number of pathological states growth differentiation factor -15, add significantly to the prognostic value of clinical information and resting ECG presenting with ischaemic sounding chest pain. The 5th generation troponin assay will be used and the range of values from 1-14ng/l will also be compared to the biomarkers studied in terms of hard cardiac endpoints. Recent studies have indicated that very low levels of detected troponin in patients with stable coronary artery disease do adversely impact on cardiac death and the development of heart failure.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
489

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2011

Longer than P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 10, 2011

Completed
7.6 years until next milestone

First Submitted

Initial submission to the registry

August 9, 2018

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 14, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

August 17, 2018

Status Verified

August 1, 2018

Enrollment Period

7.7 years

First QC Date

August 9, 2018

Last Update Submit

August 15, 2018

Conditions

Keywords

acute coronary syndrome; biomarkers, HS troponins

Outcome Measures

Primary Outcomes (1)

  • Major Adverse Cardiac Event: death, myocardial infarction, revascularisation

    All cause death, myocardial infarction and revascularisation within 3 years of index presentation

    3 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

1. Admission with chest pain which could be due to underlying ischaemic heart disease 2. HSTroponin T \< 15ng/L in patients with possible ischaemic sounding chest pain admitted to hospital at least 6 hours since onset of chest pain or in those with pain \<3hours since admission with no STEMI, a baseline HStroponin T \<15ng/l (time 0 on admission) and HSTroponin T \<15ng/l at 3 hours and \<20% increase compared to baseline (time 0) 3. Ability to give informed consent for extraction of blood for biochemical screening

You may qualify if:

  • Patients presenting within 12 hours of chest pain thought to be cardiac in origin but with no ST segment elevation on ECG
  • th generation troponin T \<15ng/l

You may not qualify if:

  • Troponin positive patients, Tn T\>=15ng/lµg/l
  • Diagnosis of non-cardiac chest pain made at outset
  • Known History of chronic heart failure or cardiomyopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Jones J, Hughes E, Dobson R, Ashrafi R, Heseltine T, Campbell M, Collinson P, Khand A. Risk Stratification of Acute Chest Pain in Patients With High-Sensitivity Troponin T Below the 99th Percentile: A Long-Term Cohort Study Assessing the Incremental Value of Necrosis and Non-necrosis Biomarkers to Clinical Risk Scores. J Am Heart Assoc. 2025 Oct 21;14(20):e040590. doi: 10.1161/JAHA.124.040590. Epub 2025 Oct 14.

Biospecimen

Retention: SAMPLES WITHOUT DNA

plasma samples to allow extraction for a range of biologically plausible biomarkers associated with elevated risk in suspected acute coronary syndromes

MeSH Terms

Conditions

Chest PainAcute Coronary Syndrome

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
consultant interventional cardiologist

Study Record Dates

First Submitted

August 9, 2018

First Posted

August 14, 2018

Study Start

January 10, 2011

Primary Completion

October 1, 2018

Study Completion

December 1, 2018

Last Updated

August 17, 2018

Record last verified: 2018-08